Literature DB >> 558741

Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism.

C R Lake, M G Ziegler, D L Murphy.   

Abstract

The sympathetic nervous system was evaluated in 11 primary autistic patients and their families. The plasma levels of norepinephrine (NE), the neurotransmitter of the sympathetic nervous system, was higher in the patients than in age-controlled normal volunteers both while supine and after standing. The plasma activity of dopamine-beta-hydroxylase, the enzyme that converts dopamine to NE, was significantly lower in the autistic patients and their healthy relatives than in control groups. Dopamine-beta-hydroxylase does not appear to provide an index of sympathetic activity in this group of patients who, on the basis of the elevated plasma levels of NE, may demonstrate a chronic state of hyperactivity of the sympathetic nervous system. Low enzyme activity found in both the autistic patients and their immediate families may be associated with this disorder.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 558741     DOI: 10.1001/archpsyc.1977.01770170063005

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  56 in total

1.  Behavioral and physiological responses to child-directed speech of children with autism spectrum disorders or typical development.

Authors:  Linda R Watson; Jane E Roberts; Grace T Baranek; Kerry C Mandulak; Jennifer C Dalton
Journal:  J Autism Dev Disord       Date:  2012-08

2.  Brief report: a double-blind study of naltrexone in infantile autism.

Authors:  M Leboyer; M P Bouvard; J M Launay; F Tabuteau; D Waller; M Dugas; B Kerdelhue; P Lensing; J Panksepp
Journal:  J Autism Dev Disord       Date:  1992-06

3.  Pupil and salivary indicators of autonomic dysfunction in autism spectrum disorder.

Authors:  Christa J Anderson; John Colombo; Kathryn E Unruh
Journal:  Dev Psychobiol       Date:  2012-05-29       Impact factor: 3.038

Review 4.  Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.

Authors:  Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

Review 5.  Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.

Authors:  Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás
Journal:  J Nutr Biochem       Date:  2018-04-19       Impact factor: 6.048

6.  Differing Developmental Trajectories in Heart Rate Responses to Speech Stimuli in Infants at High and Low Risk for Autism Spectrum Disorder.

Authors:  Katherine L Perdue; Laura A Edwards; Helen Tager-Flusberg; Charles A Nelson
Journal:  J Autism Dev Disord       Date:  2017-08

7.  Genes controlling affiliative behavior as candidate genes for autism.

Authors:  Carolyn M Yrigollen; Summer S Han; Anna Kochetkova; Tammy Babitz; Joseph T Chang; Fred R Volkmar; James F Leckman; Elena L Grigorenko
Journal:  Biol Psychiatry       Date:  2008-01-22       Impact factor: 13.382

8.  Larger tonic pupil size in young children with autism spectrum disorder.

Authors:  Christa J Anderson; John Colombo
Journal:  Dev Psychobiol       Date:  2009-03       Impact factor: 3.038

9.  Serum dopamine-beta-hydroxylase activity: clinical applications in child psychiatry.

Authors:  J G Young; R M Kyprie; N T Ross; D J Cohen
Journal:  J Autism Dev Disord       Date:  1980-03

10.  Effect of propranolol on functional connectivity in autism spectrum disorder--a pilot study.

Authors:  Ananth Narayanan; Catherine A White; Sanjida Saklayen; Mary J Scaduto; Allen L Carpenter; Amir Abduljalil; Petra Schmalbrock; David Q Beversdorf
Journal:  Brain Imaging Behav       Date:  2010-06       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.